Nucelion Therapeutics, VeGen Bio Partner on CAR-T Therapy The Story: Nucelion Therapeutics and VeGen Bio have partnered to transfer technology and manufacture VL-2511, a Phase II dual-target CAR-T the...
Key Highlights: Implications: Mankind Pharma’s €48 million investment for a 70% stake in ACTx signals a strategic shift toward high-value oncology and next-generation CAR-T therapies. ACTx...
